Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Using Qlucore Omics Explorer for Interpreting Leukemia Proteomics Data

Published: Monday, November 18, 2013
Last Updated: Monday, November 18, 2013
Bookmark and Share
Qlucore software has speeded up the process and enabled discovery for leukemia researcher Steven Kornblau.

There are many things that can be limiting factors in the research process. In the case of medical professor Steven Kornblau, the time pressures of the biological infomaticians he works with have been significant limitations.

Kornblau, a Professor of Medicine in the Department of Leukemia & Department of Stem Cell Transplantation and Cellular Therapy at UT MD Anderson Cancer Center in Houston, Texas, US, uses proteomics - the large-scale study of proteins - in the fight against leukemia. The approach that he and his colleagues take is to look simultaneously at hundreds of proteins to define patterns of protein activation in acute myeloid leukemia (AML) and identify proteins whose function are key to the survival of leukemic cells.

His laboratory developed the techniques required to use a reverse phase protein array (RPPA), which measures the relative expression levels of a protein in many samples simultaneously, for the study of leukemia and he is recognized as the leader in this field. Another key feature of Kornblau's work is the vast repository of leukemia patient samples that he has collected and can use for studies.

Kornblau and his colleagues - which includes five people in the lab, two coordinators that collect samples from the patients, and a database manager - make DNA, RNA, protein, serum and cryopreserve viable cells. He explained that ‘these materials can be used for a huge list of experiments by the researchers that we send samples to.'

Gaining insight from these many experiments is a complex task. The repository includes samples from over 2000 AML patients and the RPPA that Kornblau's team has built uses samples from 511 AML cases. This approach enables many studies to go on simultaneously, speeding up research and enabling patterns to be uncovered. However, the volumes of data are huge, particularly considering that there are around 80 different fields of clinical information for each patient, which all need to be treated differently depending whether they are simple details like the patient's name or more complicated features such as the patient's response to a particular drug or combination chemotherapy regimen. These samples are then screened against hundreds of antibodies.

The volumes and complexities of the data prevent patterns being spotted without in-depth statistical analysis that is outside the normal range of expertise of biologists, even biologists like Kornblau who also has an economics degree.

As a result, data is taken to statistician colleagues for analysis, a process that can take time as these colleagues' expertise is very much in demand. ‘I was always having to rely on statisticians. They did a great job but it involved a lot of going back and forth,' explained Kornblau.

All this changed in June 2013 when Kornblau purchased Qlucore Omics Explorer. ‘Qlucore allows me to do analysis on my own,' he said. ‘I can now check things that I know are biologically relevant on the fly.' This, he said, has ‘speeded up the process and facilitated discovery. It has definitely been a big enabler.'

The software allows Kornblau to explore his data statistically and, for example, change outlier parameters. It also enables him to generate heat maps that quickly show relevant patterns. "We can look at proteins, see why some are particularly important compared with other functionally-related proteins and look for correlations between protein clusters from one functional group. We can see how proteins are interacting with antibodies and can classify them into groups. Formerly my statistician would do all this," he observed. "The more I use the software the more I keep discovering new things."

He said that the most common functions that he uses in Qlucore Omics Explorer are the heatmap generator and the ability to do principal component analysis (PCA). He also uses the 3D functions within the PCA.

The change has been dramatic. "I've been working with protein arrays for seven years and always had to get bioinfomaticians to do the analysis. They are very much in demand so they are a rate-limiting step." In fact, he said that it usually took a couple of months to get results. "Now it is pretty easy to put my data in and I can get results within an hour - and I play with my dataset more now that I can do it myself."

Kornblau is one of the first researcher to apply the Qlucore software to proteomics.. However, he believes that it is well suited to his area of research and to other areas too.

He has found the software quite straightforward to use, with advice from Qlucore. "Like all complicated software it has a learning curve. However, once I'd learnt how the program set up its dataset there was almost nothing that I needed to do. I just had to rearrange my dataset a bit, for example to ensure that my 230 antibodies are at the end. I don't think it's any more difficult to learn than something like Excel," he explained, although he added that it does help to have some statistical background in order to get the most out of it.

And when he has found things that could be improved he has fed these ideas back to Qlucore, which is working on improvements to the software based on user feedback.

When Kornblau purchased the Qlucore solution it was following a free trial period. "I played with it pretty heavily and it was clear to me that it would be worth the money," he recounted. What's more, he has recommended it to colleagues in the proteomics space and some of them have also now purchased the tool.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Researchers Develop Animal Free Methods for Testing Chemical Compounds for Allergens
EU-funded research project developing in vitro (‘out of body’) test strategies to reduce or replace animal testing use gene expression analysis software.
Monday, April 08, 2013
New Biomarkers Could Offer Vital Clues for Cancer Research
European funding for cancer research has led to some interesting results in recent years, says Carl-Johan Ivarsson, CEO at Qlucore.
Friday, May 04, 2012
Scientific News
Breast Cancer Cells Found To Switch Molecular Characteristics
Spontaneous interconversion between HER2-positive and HER2-negative states could contribute to progression, treatment resistance in breast cancer.
Some Breast Cancer Patients With Low Genetic Risk Could Skip Chemotherapy
Genetic test can help predict survival and guide treatment options.
Symmetry is Key to Collagen
Researchers describe how symmetry may be the key to growing collagen fibres outside the body.
Lose Weight, Escape the Eight: Weight-Based Cancer Risk
IARC has identified eight additional cancer sites linked to overweight and obesity.
Unravelling the Metastatic Mechanism of Melanoma
Research has uncovered the mechanism of melanoma spreading; the findings could lead to a cure for the disease.
Gene Therapy Via Ultrasound
Research into a gene therapy approach called sonoporation could help combat heart disease and cancer.
Novel MRI Technique Distinguishes Healthy Prostate Tissue from Cancer
The UTSW researchers have determined that glucose stimulates release of the zinc ions from inside epithelial cells, which they could then track on MRIs.
Precision Nanobots Target Cancerous Tumours
Researchers achieve breakthrough toward redefining anti-cancer drug administration using nanorobotics.
PARP Proteins Explore Therapeutic Targets in Cancer
Researchers at UTSW have identified a previously unknown role of a certain class of proteins that opens the door to explore therapeutic targets in cancer and other disease.
Novel Therapeutic Approach for Blood Disorders
Gene editing of human blood-forming stem cells mimics a benign genetic condition that helps to overcome sickle cell disease and other blood disorders.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!